August 3, 2017 — Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use dual antiplatelet therapy (DAPT) after receiving a Xience everolimus-eluting coronary stent.
The study, called XIENCE Short DAPT, will evaluate if three months of DAPT is non-inferior to the current standard of 12 months after implantation with a Xience stent for patients who are at high risk of bleeding. The study will enroll approximately 2,000 patients at 100 sites in the United States and Asia.
Blood thinning medicines are prescribed for patients after stent implantation to prevent stent thrombosis, but can increase the risk for bleeding complications, particularly for high-bleeding risk patients. Approximately 1 in 5 patients who receive stents today are considered at high risk of bleeding.
“Limiting the duration of blood thinning medicine from 12 months to three months is particularly important for people at higher risk of bleeding due to factors such as older age, anemia, and renal disease," said Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine and global principal investigator of the study. “The results of this study will help determine if doctors can safely reduce the amount of time that high bleeding-risk patients must take blood thinning medication after receiving a Xience stent to unblock coronary arteries.”
XIENCE Short DAPT is a prospective, multi-center, open label, single-arm, non-randomized study. The primary endpoint is non-inferior rates of myocardial infarction or death in high-bleeding risk patients. Secondary endpoints include evaluation of the extent and severity of bleeding rates, stent thrombosis, stroke, revascularization, myocardial infarction and death.
The Xience family of everolimus-eluting coronary stent systems are indicated for improving coronary luminal diameter in patients, including people with diabetes mellitus, de novo chronic total coronary occlusions, people with symptomatic heart disease due to de novo native coronary artery lesions for Xience V (length ≤ 28 mm), Xience Prime, Xience Xpedition and Xience Alpine (lengths ≤ 32 mm) with reference vessel diameters of ≥2.25 mm to ≤ 4.25 mm.
Xience was approved in the U.S. in 2008.
For more information: www.abbott.com
August 28, 2023 
